Recent Updates
Recently added Catalysts

NgG 12.5 µg investigational vaccine

Phase 1

Sexually Transmitted Diseases | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jun 16, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment1,009

FDA Designations

No designations recorded

Clinical trial landscape

NgG 12.5 µg investigational vaccine · 1 trial · 1 indication

Phase 1 1
NCT05630859Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of AgeSexually Transmitted Diseases
COMPLETED1,009 Analytics
PHASE1COMPLETED
Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age
Sexually Transmitted DiseasesUnlock trial analytics

Study Endpoints

Primary Endpoints

Phase 1: Number of Participants Reporting Any Solicited Administration Site Events
From Day 1 to Day 7

Assessed solicited administration site events included injection site pain, erythema (redness), and swelling. Any = occurrence of the event regardless of intensity grade.

Phase 1: Number of Participants Reporting Any Solicited Systemic Events
From Day 1 to Day 7

Assessed solicited systemic events included headache, fatigue (tiredness), myalgia (muscle pain), arthralgia (joint pain), and fever (pyrexia). Fever is defined as body temperature \>=38ºC; preferred location for measuring the temperature is oral cavity. Any = occurrence of the event regardless of intensity grade.

Phase 1: Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
From Day 1 to Day 30

An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade.

Phase 1: Number of Participants Reporting Any Unsolicited AEs
From Day 61 to Day 90

An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade.

Phase 1: Number of Participants Reporting Any Serious Adverse Events (SAEs) and AEs Leading to Withdrawal
From Day 1 after the first dose to Day 241

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade.

Phase 1: Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values
At Day 8 compared to baseline (Day 1)

The safety laboratory data included haematological parameters \[hemoglobin, lymphocytes, platelets, neutrophils, and white blood cells (WBC)\] and biochemical parameters (Alanine Aminotransferase \[ALT\], Aspartate Aminotransferase \[AST\], Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 1 (baseline) and Day 8 haematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Phase 2: Incidence Rate of Confirmed Gonorrhea Cases
From 1 month post-Dose 2 (Day 91) to 13 months post-Dose 2 (Day 451)

Incidence of first confirmed gonorrhea cases by positive Nucleic Acid Amplification Test (NAAT) at the anorectal and/or urogenital location were evaluated. The incidence rate (y/PT) of confirmed gonorrhea cases, expressed in terms of 100 person-years, was calculated as the number of confirmed gonorrhea cases (y) in a group, over the sum of individual person-times at risk (PT) in the same group, and multiplied by 100.

Phase 2: Number of Participants Reporting Any Solicited Administration Site Events
From Day 1 to Day 7

Assessed solicited administration site events included injection site pain, erythema (redness), and swelling. Any = occurrence of the event regardless of intensity grade.

Phase 2: Number of Participants Reporting Any Solicited Systemic Events
From Day 1 to Day 7

Assessed solicited systemic events included headache, fatigue (tiredness), myalgia (muscle pain), arthralgia (joint pain), and fever (pyrexia). Fever is defined as body temperature \>=38ºC; preferred location for measuring the temperature is oral cavity. Any = occurrence of the event regardless of intensity grade.

Phase 2: Number of Participants Reporting Any Unsolicited AEs
From Day 1 to Day 30

An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade.

Phase 2: Number of Participants Reporting Any SAEs and AEs Leading to Withdrawal
From Day 1 after the first dose to Day 451

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcome or any other situation as determined by the investigator. An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact. Any = occurrence of the event regardless of intensity grade.

Phase 2: Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values in HIV Negative (HIV-) Subset
At Day 8 compared to baseline (Day 1)

The safety laboratory data included haematological parameters (hemoglobin, lymphocytes, platelets, neutrophils, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 1 (baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Phase 2: Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values for HIV Positive (HIV+) Subset
At Day 8 compared to baseline (Day 1)

The safety laboratory data included haematological parameters (hemoglobin, absolute lymphocyte count, platelets, absolute neutrophil count, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 1 (baseline) and Day 8 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Unknown = No results are available for the corresponding laboratory parameter at the specific timepoint.

Phase 2: Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values for HIV- Subset
At Day 68 compared to baseline (Day 61)

The safety laboratory data included haematological parameters (hemoglobin, lymphocytes, platelets, neutrophils, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 61 (baseline) and Day 68 haematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Unknown = No results are available for the corresponding laboratory parameter at the specific timepoint.

Phase 2: Number of Participants With Change From Baseline in Haematological and Biochemical Laboratory Values HIV+ Subset
At Day 68 compared to baseline (Day 61)

The safety laboratory data included haematological parameters (hemoglobin, absolute lymphocyte count, platelets, absolute neutrophil count, and WBC) and biochemical parameters (ALT, AST, Blood Urea Nitrogen and Creatinine). Categories reported when comparing Day 61 (baseline) and Day 68 hematological and biochemical laboratory results are defined as follows: \<parameter\>, \<range at baseline\>, \<range at timing\> (e.g. ALT, Within, Within). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. Unknown = No results are available for the corresponding laboratory parameter at the specific timepoint.

Secondary Endpoints

Phase 2: Incidence Rates of Confirmed Gonorrhea Cases With and Without Chlamydia Trachomatis Co-infection
From 1 month post-Dose 2 (Day 91) to 13 months post-Dose 2 (Day 451)
Phase 2: Incidence Rates of Symptomatic and Confirmed Gonorrhea Cases
From 1 month post-Dose 2 (Day 91) to 13 months post-Dose 2 (Day 451)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Phase 1: Neisseria gonorrhoeae GMMA (NgG) 12.5 micrograms (µg) GroupEXPERIMENTALParticipants received 2 doses of NgG 12.5 µg investigational vaccine on Day 1 and Day 61.
Phase 1: NgG 25 µg GroupEXPERIMENTALParticipants received 2 doses of NgG 25 µg investigational vaccine on Day 1 and Day 61.
Phase 1: NgG 50 µg GroupEXPERIMENTALParticipants received 2 doses of NgG 50 µg investigational vaccine on Day 1 and Day 61.
Phase 1: Placebo GroupPLACEBO_COMPARATORParticipants received 2 doses of placebo on Day 1 and Day 61.
Phase 2: NgG Highest tolerated dose (HTD; 50 µg) GroupEXPERIMENTALParticipants received 2 doses of NgG HTD (50 µg) investigational vaccine on Day 1 and Day 61. The HTD was selected based on the safety evaluation performed in Phase 1.
Phase 2: NgG dose below HTD (bHTD; 25 µg) GroupEXPERIMENTALParticipants received 2 doses of NgG bHTD (25 µg) investigational vaccine on Day 1 and Day 61. The bHTD is selected based on the safety evaluation performed in Phase 1.
Phase 2: Placebo GroupPLACEBO_COMPARATORParticipants received 2 doses of placebo on Day 1 and Day 61.

Interventions

NameTypeDescription
NgG 12.5 µg investigational vaccineBIOLOGICAL2 doses of NgG 12.5 µg investigational vaccine administered intramuscularly.
NgG 25 µg investigational vaccineBIOLOGICAL2 doses of NgG 25 µg investigational vaccine administered intramuscularly.
NgG 50 µg investigational vaccineBIOLOGICAL2 doses of NgG 50 µg investigational vaccine administered intramuscularly.
PlaceboCOMBINATION_PRODUCT2 doses of placebo administered intramuscularly.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes
Study Sites23

Inclusion Criteria: Inclusion criteria for the dose-escalation safety lead-in part * Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or witnessed/thumb printed informed consent obtained from the participant prior to perfor...

Countries:United StatesBrazilFranceGermanyPhilippinesSouth AfricaSpainUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMJul 17, 2026NCT05630859TRIAL_REMOVED: changed
MEDIUMJul 17, 2026NCT05630859TRIAL_REMOVED: changed
MEDIUMJul 17, 2026NCT05630859TRIAL_REMOVED: changed

Frequently asked questions about NgG 12.5 µg investigational vaccine

What is NgG 12.5 µg investigational vaccine used for?

NgG 12.5 µg investigational vaccine is being developed for the prevention of sexually transmitted diseases, specifically infections caused by Neisseria gonorrhoeae. It is an investigational vaccine intended for healthy adults aged 18 to 50 years. The vaccine is currently in clinical development and has not been approved for use.

Who makes NgG 12.5 µg investigational vaccine?

NgG 12.5 µg investigational vaccine is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the safety and efficacy of this investigational vaccine for sexually transmitted diseases.

What phase is NgG 12.5 µg investigational vaccine in?

NgG 12.5 µg investigational vaccine is in Phase 1 clinical development. It is an investigational product, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains under investigation for its safety and efficacy in preventing sexually transmitted diseases.

What clinical trials is NgG 12.5 µg investigational vaccine in?

NgG 12.5 µg investigational vaccine has one completed clinical trial registered as NCT05630859. This Phase 1 study, titled 'Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age,' enrolled 1009 participants across multiple countries including the United States, Brazil, France, Germany, Philippines, South Africa, Spain, and the United Kingdom.

Is NgG 12.5 µg investigational vaccine the same as GSK Neisseria Gonorrhoeae GMMA vaccine?

Yes, NgG 12.5 µg investigational vaccine is the same as the GSK Neisseria Gonorrhoeae GMMA (NgG) investigational vaccine. The clinical trial NCT05630859 refers to the vaccine as 'GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine,' and NgG 12.5 µg is the dose formulation being studied.